Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Patients Who Participated in ADDRESS II)

Overview

About this study

This is a multicenter, double-blind, Phase 2b, long-term extension (LTE) to the ADDRESS II core trial (EMR 700461-023) (NCT01972568), to evaluate long-term safety and tolerability of atacicept in subjects with systemic lupus erythematosus (SLE). The Week 24 visit of ADDRESS II core trial will coincide with the Day 1 visit of this LTE trial.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subjects who have completed the 24-week treatment period of trial EMR-700461-023 (ADDRESS II core trial)
  • Women of childbearing potential who have a negative pregnancy test
  • Other protocol defined inclusion criteria could apply

Exclusion Criteria:

  • Active neurological symptoms of SLE that are deemed severe or progressive
  • Diagnosis of any demyelinating disease, such as, but not restricted to, multiple sclerosis (MS) or optic neuritis
  • Pregnancy
  • Active clinically significant viral, bacterial, or fungal infection, or any major episode of infection that in the investigator's opinion makes the subject unsuitable to continue participation in the trial
  • Other protocol defined exclusion criteria could apply

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Vaidehi Chowdhary, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available
.
CLS-20169941

Mayo Clinic Footer